Results

1–7 of 7 results for avacincaptad pegol

Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: Anchored Matching-Adjusted Indirect Comparisons of Three Phase 3 Trials Over 24 Months
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2024
Characterization of Eyes With Geographic Atrophy That Developed Macular Neovascularization in the GATHER Clinical Trials
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2024
Early Progression of Atrophy in AMD: Post Hoc Analysis From the GATHER1 Study
David R Lally, MD
Annual Meeting Talks
2022
Debate: How Should We Treat Geographic Atrophy
Ajay E Kuriyan, MD, MS
Updates from the Field
2024
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, and GATHER1 Study: Results From a Post-Hoc Analysis of Nascent Geographic Atrophy
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2020